Journal for ImmunoTherapy of Cancer

Open Access

POSTER PRESENTATION

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors

Jason J Luke^{1*}, Stefani Spranger¹, Riyue Bao¹, Jorge Andrade¹, Thomas F Gajewski²

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

A subset of patients with cancer have evidence of a spontaneous anti-tumor immune response and T cell infiltration into tumor sites. This has prognostic significance and is associated with clinical response to immunotherapeutics in multiple cancers. It has been observed that high mutational load in a tumor also correlates with response to modern immunotherapies though definitive mechanistic data has yet to be shown. Molecular mechanisms underpinning the absence of a T cell response are beginning to be understood with identification specifically of the WNT/ β -catenin pathway playing a major role in melanoma.

Methods

To better understand the genetic landscape of T cellinflamed human solid tumors and to investigate molecular pathways that may mediate immune-exclusion, we performed an *in silico* analysis of The Cancer Genome Atlas (TCGA), sorting gene expression profiling and DNA sequencing data across all tumor types included. For each tumor, RNAseq data was subjected to unsupervised clustering on ~15,000 genes expressed in at least 50% of the samples.

Results

We discovered 160 genes concordantly clustered with a previously identified 13 gene immune signature across all cancers. Subsequent consensus sample clustering using the concordant genes facilitated division of each tumor into either a high, medium or low T cell-inflamed status. Simultaneously, non-synonymous exonic somatic mutations were retrieved from DNA sequencing data allowing mutational load to be associated with the presence or absence of a T cell-inflamed phenotype in individual samples. Pathway analysis was performed to

¹University of Chicago, Chicago, IL, USA

Full list of author information is available at the end of the article



© 2015 Luke et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.

identify molecular signaling pathways showing activation in low versus high T cell-inflamed tumors.

Overall the analysis identified the T cell-inflamed phenotype as being present in approximately 33% of all samples within TCGA with clear cell kidney cancer demonstrating the highest median score and uveal melanoma demonstrating the lowest score. While there was some trend between tumors known to have high mutational load and higher incidence of the T cell-inflamed tumor microenvironment, this correlation was imperfect, and within individual tumors there was no difference in mutational load between high T cell-inflamed tumors and low T cell-inflamed tumors. Pathways analysis again confirmed WNT/ β -catenin pathway activation in non-T cell-inflamed melanomas as well as other non-T cell-inflamed tumors type are under further investigation.

Conclusions

These data suggest that spontaneous anti-tumor immune priming is not driven by mutational load alone. Additionally, it appears likely that tumor-intrinsic molecular pathways will be identified in many tumor types which may suggest rational combination therapy approaches for the future.

Authors' details

¹University of Chicago, Chicago, IL, USA. ²University of Chicago Medicine, Chicago, IL, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P97

Cite this article as: Luke *et al.*: The genetic landscape of the T cell noninflamed tumor microenvironment in human solid tumors. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P97.